In November 2020, during the COVID epidemic, monoclonal antibody infusions such as bamlanivimab were identified as an effective treatment for more severe cases of SARS-CoV-2 and were given emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA, 2020)…